Posted by Michael Wonder on 08 Jun 2022
MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran
8 June 2022 - The UK medicines regulator has awarded Alnylam’s RNAi based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed to speed up NHS access to promising new medicines.
Zilebesiran (formerly ALN-AGT) is one of a new breed of gene-silencing drugs that are intended to treat common, chronic diseases with infrequent dosing to boost compliance with treatment.
